Background: it will be important to detect novel biomarkers which are responsible for progression and spread of CRC for better evaluation of patients’ prognosis, better management and development of recent therapeutic targets. Pyrroline-5-carboxylate reductase 2 (PYCR2), in humans is encoded on chromosome 1q42.12. PYCR2 metabolic activity was linked to oncogenesis in many cancers. ZBTB18, a zinc finger transcriptional repressor was found to have tumor suppressor role and was found to be methylated in CRC.
Detailed assessment of prognostic roles of PYCR2 and ZBTB18 CRC patients was not sufficiently studied.
Aim of the study was to evaluate tissue protein expression of PYCR2 and ZBTB18 in CRC and adjacent non-neoplastic intestinal tissues, to detect their roles in CRC carcinogenesis, progression and metastases.
Patients and methods: After application of inclusion criteria, sixty CRC patients were included in the study. Tissue samples from tumor and adjacent non-neoplastic tissues of included patients were stained with PYCR2 and ZBTB18.
Patients were followed up for about 30 months (range from 10-36 month). We correlate between markers expression, clinicopathological and prognostic parameters.
Results: upregulation of PYCR2 and down regulation of ZBTB18 was found in CRC than adjacent non-neoplastic colonic mucosa (p= 0.026 and p |
